Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: Reversing a pattern of failure

被引:38
作者
Argiris, A
Haraf, DJ
Kies, MS
Vokes, EE
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[2] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA
[4] Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA
关键词
head and neck cancer; chemotherapy; radiotherapy; 5-FU; hydroxyurea;
D O I
10.1634/theoncologist.8-4-350
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Combined modality programs that were developed over the past two decades demonstrated that the nonsurgical therapy of locoregionally advanced head and neck cancer is feasible and produces survival outcomes that are at least comparable with surgery. The systemic therapy of head and neck cancer has gained momentum in recent years. Several randomized studies have shown that the concurrent administration of chemotherapy and radiation therapy is superior to radiation therapy alone. In consecutive clinical studies since 1986, we have developed multiagent chemoradiotherapy regimens based on initial observations with the 5-fluorouracil (5-FU), hydroxyurea, and concomitant radiotherapy combination. Three consecutive multicenter phase 11 trials reported that the combination of 5-FU and hydroxyurea with either cisplatin or paclitaxel along with twice daily radiation therapy administered every other week is a highly effective regimen with local control rates that approach 90% and 3-year survival rates of approximately 60% in patients with stage IV disease. The vast majority of patients in these studies achieved anatomical organ preservation. A reversal of the historical pattern of failure was evident, with distant sites becoming the predominant site of failure in each trial. The paclitaxel-containing regimen was better tolerated than the cisplatin-containing regimen and was advanced to further clinical testing. The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease.
引用
收藏
页码:350 / 360
页数:11
相关论文
共 61 条
[1]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[2]   Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy [J].
Adelstein, DJ ;
Saxton, JP ;
Lavertu, P ;
Rybicki, LA ;
Esclamado, RM ;
Wood, BG ;
Strome, M ;
Carroll, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1405-1410
[3]   SPLIT-COURSE VERSUS CONTINUOUS-COURSE IRRADIATION IN THE POSTOPERATIVE SETTING FOR SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
AMDUR, RJ ;
PARSONS, JT ;
MENDENHALL, WM ;
MILLION, RR ;
CASSISI, NJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 17 (02) :279-285
[4]   Update on chemoradiotherapy for head and neck cancer [J].
Argiris, A .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (03) :323-329
[5]   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [J].
Brizel, DM ;
Albers, ME ;
Fisher, SR ;
Scher, RL ;
Richtsmeier, WJ ;
Hars, V ;
George, SL ;
Huang, AT ;
Prosnitz, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1798-1804
[6]   Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck [J].
Brockstein, B ;
Haraf, DJ ;
Stenson, K ;
Fasanmade, A ;
Stupp, R ;
Glisson, B ;
Lippman, SM ;
Ratain, MJ ;
Sulzen, L ;
Klepsch, A ;
Weichselbaum, RR ;
Vokes, EE .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :735-744
[7]   A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer [J].
Brockstein, B ;
Haraf, DJ ;
Stenson, K ;
Sulzen, L ;
Witt, ME ;
Weichselbaum, RW ;
Vokes, EE .
ANNALS OF ONCOLOGY, 2000, 11 (06) :721-728
[8]  
BROCKSTEIN BE, 2002, P AN M AM SOC CLIN, V21, pA918
[9]   PLACEBO-CONTROLLED RANDOMIZED TRIAL OF INFUSIONAL FLUOROURACIL DURING STANDARD RADIOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK-CANCER [J].
BROWMAN, GP ;
CRIPPS, C ;
HODSON, DI ;
EAPEN, L ;
SATHYA, J ;
LEVINE, MN .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2648-2653
[10]   PHASE-I AND PHASE-II TRIAL OF 5-DAY INFUSED 5-FLUOROURACIL AND RADIATION IN ADVANCED CANCER OF THE HEAD AND NECK [J].
BYFIELD, JE ;
SHARP, TR ;
FRANKEL, SS ;
TANG, SG ;
CALLIPARI, FB .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (05) :406-413